Kathryn H. Schmitz, an exercise oncology researcher at the University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, has been selected by the President’s Council on Sports, Fitness & Nutrition to receive a 2024 Lifetime Impact Award.
Arielle S. Weiss will join Fox Chase Cancer Center as assistant professor in the Division of Gynecologic Oncology in the Department of Surgery.
To address the need for nonaddictive methods to treat pain, a University of Florida team has been awarded a $3.5 million grant from NIH to train postdoctoral fellows seeking to become independent clinical pain researchers.
Cigall Kadoch was named the laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences for her work in cancer biology.
The American Association for Cancer Research will award Scarlett Lin Gomez with the 2024 AACR Distinguished Lectureship on the Science of Cancer Health Disparities during the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved to be held in Los Angeles Sept. 21-24.
Medical College of Wisconsin receives donation for pancreatic cancer research in honor of Bob Uecker
Debbie Attanasio and Milwaukee Brewers owner Mark Attanasio pledged their support to the Medical College of Wisconsin for pancreatic cancer research with a gift in honor of legendary Hall of Fame Brewers broadcaster Bob Uecker.
The University of Florida Health Adolescent and Young Adult Cancer program—one of four in the state—will add three positions to expand clinical care and services tailored to the needs of adolescents and young adults with cancer.
Mount Sinai Health System has launched its Center of Excellence for Gynecologic Cancer, which is part of The Tisch Cancer Institute. This new Center of Excellence offers a comprehensive range of services, including advanced gynecologic cancer screening and diagnosis, innovative treatments, and access to supportive care.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
Positive results from the NIAGARA phase III trial showed Imfinzi (durvalumab)in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.
